RT Journal Article
SR Electronic
T1 Diagnosing pediatric mitochondrial disease: lessons from 2,000 exomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21259171
DO 10.1101/2021.06.21.21259171
A1 Sarah L. Stenton
A1 Masaru Shimura
A1 Dorota Piekutowska-Abramczuk
A1 Peter Freisinger
A1 Felix Distelmaier
A1 Johannes A. Mayr
A1 Christine Makowski
A1 Boriana Büchner
A1 Bader Alhaddad
A1 Charlotte L. Alston
A1 Anna Ardissone
A1 Rui Ban
A1 Ivo Barić
A1 Riccardo Berutti
A1 Theresa Brunet
A1 Elżbieta Ciara
A1 Dasha Deen
A1 Julien Gagneur
A1 Daniele Ghezzi
A1 Mirjana Gusic
A1 Tobias B. Haack
A1 Maja Hempel
A1 Ralf A. Husain
A1 Daniela Karall
A1 Stefan Kölker
A1 Urania Kotzaeridou
A1 Thomas Klopstock
A1 Robert Kopajtich
A1 Vassiliki Konstantopoulou
A1 Steffen Liez
A1 Dominic Lenz
A1 Albert Z. Lim
A1 Hanna Mandel
A1 Robert McFarland
A1 Wolfgang Müller-Felber
A1 Gerard Muñoz-Pujol
A1 Akira Ohtake
A1 Yasushi Okazaki
A1 Rikke Olsen
A1 Ewa Pronicka
A1 Angela Pyle
A1 Antonia Ribes
A1 Dariusz Rokicki
A1 René Santer
A1 Manuel Schiff
A1 Markus Schuelke
A1 Dmitrii Smirnov
A1 Wolfgang Sperl
A1 Tim Strom
A1 Frederic Tort
A1 Polina Tsygankova
A1 Rudy van Coster
A1 Patrick Verloo
A1 Jürgen-Christoph von Kleist-Retzow
A1 Ekkehard Wilichowski
A1 Tekla Wolstein
A1 Manting Xu
A1 Vicente Yépez
A1 Michael Zech
A1 Saskia Wortmann
A1 Matias Wagner
A1 Costanza Lamperti
A1 Robert W. Taylor
A1 Fang Fang
A1 Agnés Rötig
A1 Kei Murayama
A1 Thomas Meitinger
A1 Holger Prokisch
YR 2021
UL http://medrxiv.org/content/early/2021/06/25/2021.06.21.21259171.abstract
AB Background The spectrum of mitochondrial disease is genetically and phenotypically diverse, resulting from pathogenic variants in over 400 genes, with aerobic energy metabolism defects as a common denominator. Such heterogeneity poses a significant challenge in making an accurate diagnosis, critical for precision medicine.Methods In an international collaboration initiated by the European Network for Mitochondrial Diseases (GENOMIT) we recruited 2,023 pediatric patients at 11 specialist referral centers between October 2010 and January 2021, accumulating exome sequencing and HPO-encoded phenotype data. An exome-wide search for variants in known and potential novel disease genes, complemented by functional studies, followed ACMG guidelines.Results 1,109 cases (55%) received a molecular diagnosis, of which one fifth have potential disease-modifying treatments (236/1,109, 21%). Functional studies enabled diagnostic uplift from 36% to 55% and discovery of 62 novel disease genes. Pathogenic variants were identified within genes encoding mitochondrial proteins or RNAs in 801 cases (72%), while, given extensive phenotype overlap, the remainder involved proteins targeted to other cellular compartments. To delineate genotype-phenotype associations, our data was complemented with registry and literature data to develop “GENOMITexplorer”, an open access resource detailing patient- (n=3,940), gene- (n=427), and variant-level (n=1,492) associations (prokischlab.github.io/GENOMITexplorer/).Conclusions Reaching a molecular diagnosis was essential for implementation of precision medicine and clinical trial eligibility, underlining the need for genome-wide screening given inability to accurately define mitochondrial diseases clinically. Key to diagnostic success were functional studies, encouraging early acquisition of patient- derived tissues and routine integration of high-throughput functional data to improve patient care by uplifting diagnostic rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge support by the German Federal Ministry of Education and Research (BMBF, Bonn, Germany) awarded grant to the German Network for Mitochondrial Disorders (mitoNET, 01GM1906A), the German BMBF and Horizon2020 through the E-Rare project GENOMIT (01GM1920A, genomit.eu), and the ERA PerMed project PerMiM (01KU2016A, permim.eu). AR and MS acknowledge the Association Francais contre les Myopathies, GIS-Institut des Maladies Rares, French Agence Nationale pour la Recherche (A.N.R.), Association contre les Maladies Mitochondriales (AMMi), Fondation Maladies Rares, Collaboration CEA/IG/CNG-INSERM, MSD-Avenir for Devo-Decode project, and Bioresources of the Necker Imagine DNA biobank (BB-033-00065). RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily Foundation and the UK NHS Specialised Commissioners who fund the Rare Mitochondrial Disorders of Adults and Children Service in Newcastle upon Tyne. CLA is supported by an NIHR postdoctoral fellowship (PDF-2018-11-ST2-02). AR, GMP, and FT were supported by the Instituto de Salud Carlos III (PI16/01048; PI19/01310) (Co-funded by European Regional Development Fund A way to make Europe) and the Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), an initiative of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion, Spain), the Departament de Salut, Generalitat de Catalunya (URDCAT project, SLT002/16/00174), the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (2017: SGR 1428) and the CERCA Programme/Generalitat de Catalunya. TK is a member of the European Reference Network for Rare Neurological Diseases (ERN-RND-Project ID No 739510). TBH was supported by the German Bundesministerium fur Bildung und Forschung (BMBF) through the Juniorverbund in der Systemmedizin mitOmics (FKZ 01ZX1405). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethikkommission Technische Universitat Munchen. Ethikkommission Ludwig-Maximilians-Universitat Munchen. Ethikkommission Bundesland Salzburg. Comitato Etico Regione Lombardia Sezione Fondazione IRCCS Istituto Neurologico "Carlo Besta". NRES Committee North East. Chiba University. Institut Imagine. Capital Medical University. Institutional Ethics Committee of the Federal State Budgetary Institution "Research Centre for Medical genetics". Commissie voor medische ethiek UZ-Gent. Ethics Committee of The Childrens Memorial Health Institute. "Comite de Etica de la Investigacion" del Hospital Clinic de Barcelona.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed for the analysis presented in the manuscript are available on GENOMITexplorer (https://prokischlab.github.io/GENOMITexplorer/). https://prokischlab.github.io/GENOMITexplorer/